[go: up one dir, main page]

DE60332846D1 - Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine - Google Patents

Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine

Info

Publication number
DE60332846D1
DE60332846D1 DE60332846T DE60332846T DE60332846D1 DE 60332846 D1 DE60332846 D1 DE 60332846D1 DE 60332846 T DE60332846 T DE 60332846T DE 60332846 T DE60332846 T DE 60332846T DE 60332846 D1 DE60332846 D1 DE 60332846D1
Authority
DE
Germany
Prior art keywords
pyrazolopyrimidines
treatment
cancer disorders
disorders
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332846T
Other languages
English (en)
Inventor
Timothy J Guzi
Kamil Paruch
Michael P Dwyer
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Alan Mallams
Carmen S Alvarez
Kartik M Keertikar
Jocelyn Rivera
Tin-Yau Chan
Vincent Madison
Thierry O Fischmann
Lawrence W Dillard
Vinh D Tran
Zhen Min He
Ray Anthony James
Haengsoon Park
Vidyadhar M Paradkar
Douglas Walsh Hobbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Pharmacopeia LLC
Original Assignee
Schering Corp
Pharmacopeia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia LLC filed Critical Schering Corp
Priority claimed from PCT/US2003/027555 external-priority patent/WO2004022561A1/en
Application granted granted Critical
Publication of DE60332846D1 publication Critical patent/DE60332846D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60332846T 2002-09-04 2003-09-03 Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine Expired - Lifetime DE60332846D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40802702P 2002-09-04 2002-09-04
US42195902P 2002-10-29 2002-10-29
PCT/US2003/027555 WO2004022561A1 (en) 2002-09-04 2003-09-03 Pyrazolopyrimidines as cyclin-dependent kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60332846D1 true DE60332846D1 (de) 2010-07-15

Family

ID=31981560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332846T Expired - Lifetime DE60332846D1 (de) 2002-09-04 2003-09-03 Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine

Country Status (12)

Country Link
EP (1) EP2194058B1 (de)
JP (1) JP2010180234A (de)
AR (1) AR041137A1 (de)
CY (1) CY1110666T1 (de)
DE (1) DE60332846D1 (de)
EC (2) ECSP055642A (de)
ES (1) ES2346204T3 (de)
MY (1) MY138201A (de)
PL (1) PL224879B1 (de)
PT (1) PT1537116E (de)
RU (1) RU2380369C9 (de)
TW (1) TWI344468B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166951A1 (en) * 2011-05-31 2012-12-06 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
CA2913791A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
JP2017538711A (ja) 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル Ｇｌｐ−１レセプターモジュレーター
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
WO2017087778A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
US20190151324A1 (en) 2016-06-23 2019-05-23 University Of Maryland, Baltimore NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF
WO2020118194A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
WO2021236449A1 (en) 2020-05-18 2021-11-25 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
WO2022093610A1 (en) 2020-10-29 2022-05-05 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonmide di-hydrochloride di-hydrate
AU2022244224B9 (en) 2021-03-23 2025-01-30 Gen1E Lifesciences Inc. Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907799A (en) 1971-08-16 1975-09-23 Icn Pharmaceuticals Xanthine oxidase inhibitors
JPH05507702A (ja) 1990-05-30 1993-11-04 アメリカン・ホーム・プロダクツ・コーポレイション 置換アリールスルホンアミド類およびベンズアミド類
DK0591528T3 (da) 1991-04-22 1999-08-23 Otsuka Pharma Co Ltd Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette
EP0628559B1 (de) * 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidinverbindungen und ihre Verwendung als Pharmazeutika
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5707997A (en) 1994-06-21 1998-01-13 Otsuka Pharmaceutical Factory, Inc. Pyrazolo 1,5-a!pyrimidine derivative
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999030710A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE253076T1 (de) 1998-08-14 2003-11-15 Pfizer Antithrombosemittel
EP1124823A1 (de) 1998-10-30 2001-08-22 Merck & Co., Inc. Thrombin inhibitoren
PT1140944E (pt) 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
EP1140938B1 (de) 1999-01-11 2003-08-27 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
EP1196411B1 (de) 1999-07-15 2003-09-17 Pharmacopeia, Inc. Bradikinin b1 rezeptor antagonisten
GEP20043367B (en) 2000-07-26 2004-06-10 Bristol Myers Squibb Co N-[5-[[[5-Alkyl-2-Oxazolyl]Methyl]Thio]-2-Thiazolyl Carboxamide Inhibitors of Cyclin Dependent Kinases
NZ525016A (en) 2000-09-15 2004-10-29 Vertex Pharma Isoxazoles and their use as inhibitors of ERK
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
AU2509602A (en) * 2000-12-20 2002-07-01 Sod Conseils Rech Applic Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors

Also Published As

Publication number Publication date
RU2005109543A (ru) 2006-05-10
RU2380369C2 (ru) 2010-01-27
RU2380369C9 (ru) 2011-07-10
TWI344468B (en) 2011-07-01
ECSP055642A (es) 2005-05-30
PL375697A1 (en) 2005-12-12
PL224879B1 (pl) 2017-02-28
CY1110666T1 (el) 2015-06-11
PT1537116E (pt) 2010-09-03
JP2010180234A (ja) 2010-08-19
EP2194058A1 (de) 2010-06-09
ECSP11005642A (es) 2011-10-31
MY138201A (en) 2009-05-29
TW200410973A (en) 2004-07-01
ES2346204T3 (es) 2010-10-13
AR041137A1 (es) 2005-05-04
EP2194058B1 (de) 2013-11-27

Similar Documents

Publication Publication Date Title
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
DE602004030907D1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE462708T1 (de) Zur behandlung von hyperproliferationserkrankungen und mit angiogenese assoziierten krankheiten geeignete pyrrolotriazinderivate
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
EP1664051A4 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren zur behandlung von proliferativen erkrankungen
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60327074D1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
DE60332846D1 (de) Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
ATE423099T1 (de) Zur behandlung von schmerzen geeignete piperazine
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
AU2003259833A8 (en) Methods of treating neurodegenerative diseases
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
EP1663318A4 (de) Radioisotop-chitosan-komplex zur behandlung von prostatakrebs
EP1372639A4 (de) Mittel zur behandlung von reizblasensymptomen mit begleitender benigner prostatahyperplasie